Compare McKesson Corporation (MCK) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Invesco S&P 500 Low Volatility ETF — how do they compare? McKesson Corporation trades at $823.53 (market cap $97.35B), while Invesco S&P 500 Low Volatility ETF trades at $75.71. The key difference: McKesson Corporation pays a 0.39% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | SPLV | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | — |
52-Week High | $995.69 | $77.45 |
52-Week Low | $659.01 | $70.30 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
SPLV trades at $76.09, down 0.63% today, with a bullish technical outlook supported by moving averages and key support at $76. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty, with recent news highlighting its defensive appeal during tech sell-offs and geopolitical tensions. Dividend distributions are scheduled for mid-2026 at $0.14 per share.
Outlook remains positive for risk-averse investors seeking equity exposure with reduced volatility, though reliance on market sentiment and interest rate trends poses risks. The ETF's strategy aligns with current defensive positioning, but limited growth potential may cap upside compared to broader market indices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
